Inspire(US:INSP) Globenewswire·2026-01-12 11:45Core Insights - Inspire Medical Systems announced the appointment of Matt Osberg as Executive Vice President and Chief Financial Officer, effective January 19, 2026 [3][4] - The company provided preliminary, unaudited revenue results for the fourth quarter and full year 2025, with fourth quarter revenue expected to be between $268.9 million and $269.1 million, representing a 12% increase year-over-year [6] - For the full year 2025, revenue is anticipated to be in the range of $911.8 million to $912.0 million, marking a 14% increase compared to 2024 [6] - Inspire's revenue guidance for 2026 is projected to be between $1,003 million and $1,013 million, indicating a growth of 10% to 11% over 2025 [2] Financial Performance - The fourth quarter revenue for 2025 is expected to show a strong performance, contributing to the overall positive momentum for the company [2] - The company experienced significant growth in the second half of 2025, particularly following the launch of the Inspire V system [2] - Inspire's revenue growth outlook for 2026 does not currently factor in potential increases from reimbursement developments [2] Leadership Changes - Matt Osberg brings over 20 years of financial leadership experience to Inspire, having previously served as CFO at Apogee Enterprises and Helen of Troy [3][4] - The appointment of Osberg is seen as a strategic move to guide the company through its next growth phase [4] Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for obstructive sleep apnea [8] - The company's Inspire therapy is recognized as the first FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [8]